Xiaojing Shi

Xiaojing SHI is a Senior Scientist at Capsida Biotherapeutics, specializing in capsid engineering since August 2020, with prior roles as Scientist II and Scientist. From January 2015 to May 2020, Xiaojing served as a Graduate Research Assistant at the University of Southern California, developing exosome-based cancer immunotherapeutics under the guidance of Dr. Yong (Tiger) Zhang. A summer internship at Denali Therapeutics in 2019 involved isolating exosomes from various human biosamples and collaborating with an omics mass spectrometry group. Earlier experiences include research at Tsinghua University focused on TGF-β signaling interactions and a visiting research position at Tel Aviv University tasked with developing a bacterial genetic system. Xiaojing holds a PhD in Pharmaceutical Sciences and an MS in Regulatory Sciences from the University of Southern California, as well as a B.Sc. in Life Sciences from Tsinghua University.